Daiichi Sankyo

News

EU starts review of Enhertu in HER2-ultra-low breast cancer

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER

News

MSD, Daiichi Sankyo lung cancer ADC starts phase 3

One of three antibody-drug conjugates licensed by MSD for $4 billion upfront last year has started phase 3 testing in a form of lung cancer.

News

Image of the word No in gold neon lights

NICE blocks Enhertu use after pricing talks break down

NICE and drugmakers AstraZeneca and Daiichi Sankyo have all expressed their disappointment at being unable to agree on a price for Enhertu that would allow it to be used on the NHS for peop

News

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

The FDA has said it cannot approve MSD and Daiichi Sankyo’s HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan because of problems at a third-party manufacturer.

News

Daiichi Sankyo’s Ezharmia cleared in Japan for rare lymphoma

Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).

News